<DOC>
	<DOCNO>NCT02699372</DOCNO>
	<brief_summary>This randomize , single center , adaptive single ascend dose ( Part 1 ) multiple ascend dose ( Part 2 ) study design assess safety , tolerability , pharmacokinetic , pharmacodynamics follow oral administration RO6889450 versus placebo healthy volunteer . The anticipated duration study approximately 18 week .</brief_summary>
	<brief_title>The Safety , Tolerability , Pharmacokinetics Pharmacodynamics Study RO6889450 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>A body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) inclusive Body weight range 50 100 kilogram ( kg ) righthanded Part 2 For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure , agreement refrain donate sperm Fluent language Investigator study staff ( include raters ) Able participate comply study restriction Part 1 Part 2 : Disorders central nervous system ( CNS ) , psychiatric disorder , behavioral disturbance Participants , Investigator 's judgment , pose suicidal homicidal risk Any personal familial history ( first degree ) seizures , epilepsy convulsive condition Positive family history psychosis mood disorder first degree relative Angle closure glaucoma , history current significant ophthalmologic neurologic condition would adversely affect pupillometry assessment Suspicion regular consumption drug abuse and/or history alcohol addiction positive urine drug screen and/or positive alcohol urine test , regular smoker Positive result hepatitis B ( HBV ) , hepatitis C ( HCV ) , human immunodeficiency virus antibody ( HIV 1 2 ) Any prescribed OTC medication ( include vitamin herbal remedy ) take within 4 week prior first dose within 5 time elimination halflife medication prior first dosing ( whichever longer ) Taking nutrient know modulate CYP3A activity ( e.g. , grapefruit juice ; Seville orange ) within 2 week prior administration study drug Clinically significant abnormality laboratory test result ( include hepatic renal panel , complete blood count , chemistry panel urinalysis ) Participation investigational drug device study within 90 day prior screen Dietary restriction would prohibit consumption standardize meal Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk participant study Part 2 : Contraindications magnetic resonance imaging ( MRI ) scan brain/head abnormality restrict MRI eligibility . Any sensorial impairment deafness reduce visual acuity correct fMRI scanner Use psychoactive medication , medication know effect CNS blood flow take within 4 week prior first dose within 5 time elimination halflife medication prior first dosing ( whichever longer ) Fulfilment MRI contraindication standard radiography screening questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>